Leading brokers name 3 ASX shares to buy today

Analysts believe that now could be the time to add these shares to your portfolio…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares that leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate

Image source: Getty Images

Coles Group Ltd (ASX: COL)

According to a note out of Citi, its analysts have retained their buy rating and $20.20 price target on this supermarket operator's shares. This follows the release of a quarterly update from Coles last week, which came in a touch ahead of Citi's forecasts. The broker believes that the company's private label offering has been a key driver of this outperformance and appears to believe the trend can continue. The Coles share price is fetching $18.29 this afternoon.

Coronado Global Resources Inc (ASX: CRN)

A note out of Goldman Sachs reveals that its analysts have retained their buy rating on this coal miner's shares with an increased price target of $2.20. This follows the release of a quarterly update that was in-line with expectations. Goldman continues to see Coronado as a great option due to its strong free cash flow and dividend yield, as well as a supportive met coal market on supply risks and China's reopening. The Coronado Global share price is trading at $1.68 today.

ResMed Inc. (ASX: RMD)

Analysts at Goldman Sachs have also retained their buy rating on this sleep treatment company's shares with an improved price target of $39.60. This follows the release of a solid quarterly update from ResMed last week. Goldman was pleased with what it saw and has upgraded its revenue and earnings estimates through to FY 2026. The broker also continues to see a long-duration runway of HSD organic growth and highlights that its shares trade on lower than normal multiples. The ResMed share price is trading at $35.84 on Monday.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended Coles Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A woman in a red dress holding up a red graph.
Broker Notes

3 ASX shares with 39% to 141% growth ahead of them: Experts

If you're looking for capital gains, try these shares on for size.

Read more »

A young man talks tech on his phone while looking at a laptop with a financial graph superimposed across the image.
Broker Notes

Buy, hold, sell: How does Morgans rate these ASX shares?

One of these shares could deliver a 50% return according to the broker.

Read more »

Three generation of women cuddling and smiling together.
Broker Notes

3 reasons to buy the dip on Life360 shares today

A leading analyst believes Life360 shares are well-placed to outperform. But why?

Read more »

An oil refinery worker checks her laptop computer in front of a backdrop of oil refinery infrastructure.
Broker Notes

With oil prices falling, should I still buy Santos shares now?

A leading analyst provides his forecast for Santos' outperforming share price.

Read more »

Two ASX share investors sharing a secret.
Broker Notes

Buy, hold, sell: Flight Centre, Supply Network, Lottery Corporation shares

Experts reveal their ratings on three ASX shares in the consumer discretionary sector.

Read more »

Six smiling health workers pose for a selfie.
Broker Notes

Buy, hold, sell: Charter Hall, Northern Star, Cochlear shares

We review three fresh buy, hold, and sell calls from expert market analysts.

Read more »

Buy, hold, and sell ratings written on signs on a wooden pole.
Broker Notes

Down 53%, is it time to throw in the towel on CSL shares?

A leading analyst delivers his verdict on CSL’s plunging share price.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

Up 293%! Can Electro Optic Systems (EOS) shares keep rising?

Bell Potter believes this high-flying stock hasn't peaked yet.

Read more »